PATINA supports adding palbociclib to anti-HER2 plus endocrine therapy in HR+/HER2+ disease, and HER2CLIMB-05 validates tucatinib with HP after THP induction. Sequencing trials must address ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results